$EDIT
Editas Medicine Inc

2024 Q4 Form 10-Q Financial Statement

#000165066424000121 Filed on November 04, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $61.00K
YoY Change -98.86%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.09M
YoY Change 20.67%
% of Gross Profit
Research & Development $47.64M
YoY Change 17.59%
% of Gross Profit
Depreciation & Amortization $1.599M
YoY Change 5.2%
% of Gross Profit
Operating Expenses $65.73M
YoY Change 18.43%
Operating Profit -$65.67M
YoY Change 30.91%
Interest Expense $3.530M
YoY Change -31.32%
% of Operating Profit
Other Income/Expense, Net $3.525M
YoY Change -31.47%
Pretax Income -$62.14M
YoY Change 38.03%
Income Tax
% Of Pretax Income
Net Earnings -$62.14M
YoY Change 38.03%
Net Earnings / Revenue -101870.49%
Basic Earnings Per Share -$0.75
Diluted Earnings Per Share -$0.75
COMMON SHARES
Basic Shares Outstanding 82.55M shares 82.48M shares
Diluted Shares Outstanding 82.49M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $265.1M
YoY Change -24.17%
Cash & Equivalents $95.83M
Short-Term Investments $169.3M
Other Short-Term Assets $5.925M
YoY Change -10.23%
Inventory
Prepaid Expenses
Receivables $126.0K
Other Receivables $0.00
Total Short-Term Assets $271.1M
YoY Change -24.39%
LONG-TERM ASSETS
Property, Plant & Equipment $15.42M
YoY Change 33.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $5.281M
YoY Change -8.24%
Total Long-Term Assets $56.43M
YoY Change -61.36%
TOTAL ASSETS
Total Short-Term Assets $271.1M
Total Long-Term Assets $56.43M
Total Assets $327.6M
YoY Change -35.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.49M
YoY Change 19.98%
Accrued Expenses $28.79M
YoY Change -4.93%
Deferred Revenue $14.68M
YoY Change 78.62%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.35M
YoY Change 23.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $3.281M
YoY Change -96.17%
Total Long-Term Liabilities $3.281M
YoY Change -96.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.35M
Total Long-Term Liabilities $3.281M
Total Liabilities $151.9M
YoY Change 5.37%
SHAREHOLDERS EQUITY
Retained Earnings -$1.400B
YoY Change 16.67%
Common Stock $1.598B
YoY Change 1.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $175.6M
YoY Change
Total Liabilities & Shareholders Equity $327.6M
YoY Change -35.09%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$62.14M
YoY Change 38.03%
Depreciation, Depletion And Amortization $1.599M
YoY Change 5.2%
Cash From Operating Activities -$52.59M
YoY Change 48.3%
INVESTING ACTIVITIES
Capital Expenditures $2.921M
YoY Change 1117.08%
Acquisitions
YoY Change
Other Investing Activities $86.90M
YoY Change -184.71%
Cash From Investing Activities $83.98M
YoY Change -181.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -52.59M
Cash From Investing Activities 83.98M
Cash From Financing Activities 0.000
Net Change In Cash 31.39M
YoY Change -122.7%
FREE CASH FLOW
Cash From Operating Activities -$52.59M
Capital Expenditures $2.921M
Free Cash Flow -$55.51M
YoY Change 55.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0001650664
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Small Business
EntitySmallBusiness
false
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
60667000 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82538624 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82538624 shares
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18088000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
65727000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
55499000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65666000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50163000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
3530000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
5144000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3525000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86415000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Investment Income Net
InvestmentIncomeNet
12861000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
12464000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12861000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10874000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-62141000 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3281000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1800000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
151933000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
150056000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81767263 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81767263 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ServiceMember
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35728000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1598152000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5144000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ServiceMember
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
EDITAS MEDICINE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4097528
dei Entity Address Address Line1
EntityAddressAddressLine1
11 Hurley Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
401-9000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
EDIT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82548099 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95832000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123652000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
169256000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
199459000 usd
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
126000 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
10187000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5925000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7531000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
271139000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
340829000 usd
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
104024000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15419000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12032000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33680000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5281000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8588000 usd
CY2024Q3 us-gaap Assets
Assets
327567000 usd
CY2023Q4 us-gaap Assets
Assets
499153000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12491000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8269000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28785000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34563000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14684000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8221000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16393000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12164000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
72353000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63217000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22095000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24372000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
54204000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1580241000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
522000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
198000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1423048000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1231350000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
175634000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
349097000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
327567000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
499153000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5336000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1710000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18074000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47639000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40512000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
150636000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
108095000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14987000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
55633000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
55198000 usd
us-gaap Operating Expenses
OperatingExpenses
206269000 usd
us-gaap Operating Expenses
OperatingExpenses
163293000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-204559000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-145219000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1590000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45019000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191698000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134345000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82485199 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82485199 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81648250 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81648250 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82245679 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82245679 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74029645 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74029645 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-62141000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45019000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191698000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134345000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
964000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
833000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
324000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2149000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61177000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44186000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-191374000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132196000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
349097000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
192000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7585000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-524000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-61950000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
294400000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5010000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
322000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-116000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-67607000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
232009000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4802000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
964000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-62141000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
175634000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
360680000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4507000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1322000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-49036000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
317473000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117079000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5215000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
435000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-40290000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
399917000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4731000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
833000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45019000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
360462000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191698000 usd
us-gaap Net Income Loss
NetIncomeLoss
-134345000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17397000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
14453000 usd
us-gaap Depreciation
Depreciation
4428000 usd
us-gaap Depreciation
Depreciation
4598000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-139000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1583000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4922000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2720000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
415000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10061000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2723000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1607000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-771000 usd
edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
2048000 usd
edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-11712000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3306000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
502000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4713000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1102000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5523000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
22000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1952000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9335000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1481000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159522000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109938000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8286000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3412000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
86221000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
219764000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
225695000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
156605000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
131188000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66571000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117079000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
192000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
322000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
435000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
514000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117525000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27820000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58984000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127529000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145399000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99709000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95832000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82537000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
3877000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
3878000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99709000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86415000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
3877000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
3878000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
134000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
12565000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
9103000 usd
edit Remeasurement Of Operating Lease Liabilities And Right Of Use Assets Due To Lease Modification
RemeasurementOfOperatingLeaseLiabilitiesAndRightOfUseAssetsDueToLeaseModification
794000 usd
edit Remeasurement Of Operating Lease Liabilities And Right Of Use Assets Due To Lease Modification
RemeasurementOfOperatingLeaseLiabilitiesAndRightOfUseAssetsDueToLeaseModification
1069000 usd
edit Commencement Of Right Of Use Asset
CommencementOfRightOfUseAsset
7844000 usd
edit Commencement Of Right Of Use Asset
CommencementOfRightOfUseAsset
0 usd
edit Modification Of Right Of Use Asset
ModificationOfRightOfUseAsset
1954000 usd
edit Modification Of Right Of Use Asset
ModificationOfRightOfUseAsset
0 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Business<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Editas Medicine, Inc. (the “Company”) is a clinical stage gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers Squibb Company (“BMS”), payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”) and payments received in connection with the Company’s license agreement with Vertex Pharmaceuticals, Inc. (“Vertex”) and other payments under the Vertex license agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2023, the Company completed a public offering in which it sold 12,500,000 shares of its common stock and received net proceeds of approximately $117.1 million after deducting underwriting discounts and commissions and other offering costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). The Company amended the common stock sales agreement with Cowen in February 2024 in connection with filing a new registration statement. As of September 30, 2024, the Company has not sold any shares of its common stock under the ATM Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred annual net operating losses in every year since its inception. As of November 4, 2024, the issuance date of the consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the consolidated financial statements. The Company had an accumulated deficit of $1.4 billion at September 30, 2024, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</span></div>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400000000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
264566000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
553000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
265088000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
426937000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
611000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
413000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
427135000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
3 security
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2000 usd
CY2024Q3 edit Marketable Securities Noncurrent Number Of Securities
MarketableSecuritiesNoncurrentNumberOfSecurities
0 security
edit Marketable Securities Remaining Maturity Term
MarketableSecuritiesRemainingMaturityTerm
P1Y
CY2024Q3 edit Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
13839000 usd
CY2023Q4 edit Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
16204000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11939000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11280000 usd
CY2024Q3 edit Sublicense And License Fees
SublicenseAndLicenseFees
0 usd
CY2023Q4 edit Sublicense And License Fees
SublicenseAndLicenseFees
5063000 usd
CY2024Q3 edit Intellectual Property And Patent Related Fees
IntellectualPropertyAndPatentRelatedFees
1610000 usd
CY2023Q4 edit Intellectual Property And Patent Related Fees
IntellectualPropertyAndPatentRelatedFees
983000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
831000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
750000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
566000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
283000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28785000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34563000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
45949000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38292000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30530000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26260000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15419000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12032000 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
10187000 usd
edit Accounts Receivable Additions
AccountsReceivableAdditions
503000 usd
edit Accounts Receivable Deductions
AccountsReceivableDeductions
10564000 usd
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
126000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
68888000 usd
edit Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0 usd
edit Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
0 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
68888000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4802000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4731000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17397000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14453000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10708400 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8105909 shares
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001650664-24-000121-index-headers.html Edgar Link pending
0001650664-24-000121-index.html Edgar Link pending
0001650664-24-000121.txt Edgar Link pending
0001650664-24-000121-xbrl.zip Edgar Link pending
edit-20240930.htm Edgar Link pending
edit-20240930.xsd Edgar Link pending
edit-20240930xex311.htm Edgar Link pending
edit-20240930xex312.htm Edgar Link pending
edit-20240930xex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
edit-20240930_cal.xml Edgar Link unprocessable
edit-20240930_def.xml Edgar Link unprocessable
edit-20240930_lab.xml Edgar Link unprocessable
edit-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
edit-20240930_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending